TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17180572

Group type: EXPERIMENTAL
Intervention: Hydration therapy only
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Hemodialysis once
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Patients with elevated creatinine at 30-60 days
Number of subjects: 424
Study: 15509041

Group type: EXPERIMENTAL
Intervention: Bioadhesive plaster of diclofenac epolamine (Flector Plaster)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11724094

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study: 9630824

Group type: EXPERIMENTAL
Intervention: Single oral dose of 1 gm mycophenolate mofetil
Number of subjects: 5
Study: 7524456

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose thromboplastin
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose thrombin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activated clotting time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose thromboplastin and high-dose thrombin measurements
Number of subjects: 0
Study: 3584744

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 61

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (50 micrograms per actuation)
Number of subjects: 61
Study: 31972655

Group type: EXPERIMENTAL
Intervention: Remimazolam continuous intravenous infusion (5 mg/min for 5 min, 3 mg/min for 15 min, 1 mg/min for 15 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remimazolam continuous intravenous infusion
Number of subjects: 20
Study: 29548834

Group type: EXPERIMENTAL
Intervention: Standardized oral consent and written information sheet (Group 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standardized oral informed consent (Group 1)
Number of subjects: 28
Study: 27501080

Group type: EXPERIMENTAL
Intervention: Organizational-level occupational health intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 196
Study: 24290575

Group type: EXPERIMENTAL
Intervention: Surgical resection (open surgery)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 1018
Study: 23882695

Group type: EXPERIMENTAL
Intervention: Occlusion therapy for amblyopia (6 hours/day in MOTAS; randomized to 6 or 12 hours/day in ROTAS)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Occlusion therapy on weekends
Number of subjects: 152

Group type: COMPARATOR
Intervention: Occlusion therapy with less frequent attendance
Number of subjects: 152

Group type: COMPARATOR
Intervention: Occlusion therapy with prolonged treatment duration
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Different subpopulations of patch day doses
Number of subjects: 152
Study: 20667550

Group type: EXPERIMENTAL
Intervention: Transtelephonic electrocardiogram (TTECG) monitoring
Number of subjects: 92

Group type: COMPARATOR
Intervention: Electrocardiogram and 24-hour Holter monitoring
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TTECG monitoring
Number of subjects: 92
Study: 18982782

Group type: EXPERIMENTAL
Intervention: Propofol TCI (5 ng L(‐1) remifentanil, 2.8 microg mL(‐1) propofol)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sevoflurane (8%)
Number of subjects: 44
Study: 17083356

Group type: EXPERIMENTAL
Intervention: Shrimp-derived glucosamine (1,500 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Synthetic glucosamine (1,500 mg)
Number of subjects: 15
Study: 11881630

Group type: EXPERIMENTAL
Intervention: 3 suprastructure modalities (specific types not detailed)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clenching without implant support
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clenching with implant support
Number of subjects: 18
Study: 10544835

Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 40
Study: 7551918

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with preoperative radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 1693711

Group type: EXPERIMENTAL
Intervention: Felodipine added to beta-blocker
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Felodipine monotherapy
Number of subjects: 471
Study: 471965

Group type: EXPERIMENTAL
Intervention: Health education materials and follow-up visit
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no health education materials)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Health education materials
Number of subjects: 54
Study: 31934950

Group type: EXPERIMENTAL
Intervention: Fractional microablative CO2 laser treatment
Number of subjects: 40
Study: 31134707

Group type: EXPERIMENTAL
Intervention: Dietitian Group (DG) - advised by dietitians in six weekly face-to-face behavioural therapy sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physician Group (PG) - received standard advice from physicians
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dietitian Group (DG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physician Group (PG)
Number of subjects: 100
Study: 29072977

Group type: EXPERIMENTAL
Intervention: AC followed by Paclitaxel and Trastuzumab
Number of subjects: 407

Group type: COMPARATOR
Intervention: AC followed by Paclitaxel
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index (DASI) scores
Number of subjects: 407
Study: 25814318

Group type: EXPERIMENTAL
Intervention: Pinocembrin 20-150 mg single ascending doses
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pinocembrin 60 mg multiple doses
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23479384

Group type: EXPERIMENTAL
Intervention: Cetuximab (week 1: 400 mg/m²; subsequent weeks: 250 mg/m²) plus cisplatin (100 mg/m², day 1) and 5-fluorouracil (1000 mg/m²/day, 24-h infusion, days 1-4)
Number of subjects: 33
Study: 21849487

Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone (VD)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Reduced-dose bortezomib, thalidomide plus dexamethasone (vtD)
Number of subjects: 199
Study: 18809176

Group type: EXPERIMENTAL
Intervention: Referential communication tasks; measures of inhibitory control, working memory, and cognitive flexibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speaker's perspective in interpreting instructions
Number of subjects: 0
Study: 17156835

Group type: EXPERIMENTAL
Intervention: Fight Cancer with Fitness! (FCF) intervention
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 366
Study: 15480324

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg/d
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 11709567

Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (CMT) consisting of three cycles of doxorubicin and vinblastine followed by subtotal lymphoid irradiation (STLI)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Subtotal lymphoid irradiation (STLI)
Number of subjects: 348
Study: 9118690

Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuit
Number of subjects: 14

Group type: COMPARATOR
Intervention: Noncoated extracorporeal circuit
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 8441570

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam, 0.4 mg/kg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo/control group
Number of subjects: 59
Study: 2876183

Group type: EXPERIMENTAL
Intervention: 1 g calcium per day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31789965

Group type: EXPERIMENTAL
Intervention: Protective ventilation (Low tidal volume of 6 ml/kg predicted body weight during two-lung ventilation and 3 ml/kg predicted body weight during one-lung ventilation with 5 cmH2O positive end-expiratory pressure)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional ventilation (Intermediate tidal volume of 10 ml/kg predicted body weight during two-lung ventilation and 5 ml/kg predicted body weight during one-lung ventilation with no positive end-expiratory pressure)
Number of subjects: 29
Study: 30413407

Group type: EXPERIMENTAL
Intervention: Alpelisib plus fulvestrant endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 0
Study: 28628843

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and chemoradiotherapy (CRT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 119
Study: 25719725

Group type: EXPERIMENTAL
Intervention: Cograft of acellular dermal matrix with autologous split-thickness skin graft (group A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Autologous split-thickness skin graft alone (group B)
Number of subjects: 19
Study: 22984204

Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing quadruple therapy (EBTL group): 40 mg of esomeprazole twice daily, 300 mg of bismuth subcitrate four times daily, 500 mg of tetracycline four times daily, and 500 mg of levofloxacin once daily for 10 days (n = 76)
Number of subjects: 150

Group type: COMPARATOR
Intervention: High-dose metronidazole-based quadruple therapy (EBTM group): 40 mg of esomeprazole twice daily, 300 mg of bismuth subcitrate four times daily, 500 mg of tetracycline four times daily, and 500 mg of metronidazole four times daily for 10 days (n = 74)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing quadruple therapy (EBTL group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: High-dose metronidazole-based quadruple therapy (EBTM group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 22073795

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (60 mg elemental iron)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 19194499

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP) plus artesunate (AS)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP) alone
Number of subjects: 191

Group type: COMPARATOR
Intervention: Double mutant infections
Number of subjects: 191
Study: 16814950

Group type: EXPERIMENTAL
Intervention: 30 Gy in 10 fractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8 Gy in 1 fraction
Number of subjects: 0
Study: 15046441

Group type: EXPERIMENTAL
Intervention: Arthrodiastasis for approximately four months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional treatment (historical control group)
Number of subjects: 45
Study: 11111188

Group type: EXPERIMENTAL
Intervention: Neoadjuvant total androgen deprivation using a LHRH analogue (goserelin) plus flutamide for a period of 3 months
Number of subjects: 402

Group type: COMPARATOR
Intervention: Radical prostatectomy only
Number of subjects: 402
Study: 8915150

Group type: EXPERIMENTAL
Intervention: Diphencyprone (DPCP) treatment, 2% solution, applied once a week for at least 3 months, up to 1 year.
Number of subjects: 26
Study: 1347854

Group type: EXPERIMENTAL
Intervention: Artesunate (600 mg over 5 days)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Mefloquine (750 mg then 500 mg 6 h later)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Artesunate followed by mefloquine
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Combination of artesunate and mefloquine
Number of subjects: 127
Study: 2859204

Group type: EXPERIMENTAL
Intervention: BW 825C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triprolidine (2.5 mg and 5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2957398

Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.05% gel
Number of subjects: 268

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 268
Study: 31365710

Group type: EXPERIMENTAL
Intervention: L8020 yogurt
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 23
Study: 28485828

Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 288

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 288
Study: 25182079

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study: 23092741

Group type: EXPERIMENTAL
Intervention: Web-based nutrition education (n=57)
Number of subjects: 123

Group type: COMPARATOR
Intervention: In-person nutrition education (n=66)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Web-based nutrition education
Number of subjects: 123
Study: 21659439

Group type: EXPERIMENTAL
Intervention: Hydrophilic polymer-coated zotarolimus-eluting stent (ZES)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fluoropolymer-coated everolimus-eluting stent (EES)
Number of subjects: 58
Study: 17764096

Group type: EXPERIMENTAL
Intervention: Treatment arm
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1356
Study: 17069543

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 14625623

Group type: EXPERIMENTAL
Intervention: Supplementation with folate (5-methyl-tetrahydrofolate), vitamin B6, and B12
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Supplementation with omega-3 fatty acids
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study: 11132613

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg o.d. (n = 15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Felodipine 5-10 mg o.d. (n = 15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lacidipine 4-6 mg o.d. (n = 15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manidipine 10-20 mg o.d. (n = 15)
Number of subjects: 60
Study: 9163255

Group type: EXPERIMENTAL
Intervention: Furosemide-containing suppositories (Massa Estarinum 299)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Furosemide Sodium suppositories
Number of subjects: 8
Study: 1590228

Group type: EXPERIMENTAL
Intervention: Pirenzepine (2 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (1 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline solution (2 ml)
Number of subjects: 25
Study: 2859054

Group type: EXPERIMENTAL
Intervention: Ceruletide (0.6 microgram/kg im)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31151437

Group type: EXPERIMENTAL
Intervention: TIME intervention in intervention nursing homes (INH)
Number of subjects: 807
Study: 28765003

Group type: EXPERIMENTAL
Intervention: Vaccine (VAC)
Number of subjects: 268896

Group type: EXPERIMENTAL
Intervention: Non-vaccinated individuals in vaccinated communities
Number of subjects: 268896

Group type: COMPARATOR
Intervention: Non-intervention (non-vaccinated communities)
Number of subjects: 268896
Study: 25954841

Group type: EXPERIMENTAL
Intervention: Electronic device
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mechanical disc calculator
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pen and paper method
Number of subjects: 21
Study: 24164697

Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS) for 16 weeks
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS) with participant payments of £1 per session
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS) with participant payments of £2 per session
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Participants with mental health risk factors
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Participants with chronic heart disease risk factors only
Number of subjects: 798
Study: 21485728

Group type: EXPERIMENTAL
Intervention: Alexis wound retractor
Number of subjects: 231

Group type: COMPARATOR
Intervention: Conventional Doyen retractor
Number of subjects: 231
Study: 19289389

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 772

Group type: COMPARATOR
Intervention: Mediterranean-style diets
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Increased dietary fibre intake
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Increased soluble fibre intake
Number of subjects: 772
Study: 17348882

Group type: EXPERIMENTAL
Intervention: Implantoplasty (test group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Resective surgery (control group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of implantoplasty vs resective surgery
Number of subjects: 19
Study: 15190963

Group type: EXPERIMENTAL
Intervention: 80 mg of a monoclonal anti-IL-6 Ab (B-E8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12174332

Group type: EXPERIMENTAL
Intervention: Indoor rehabilitation (rehabilitation group, RG)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Ambulant group (control)
Number of subjects: 195
Study: 11477830

Group type: EXPERIMENTAL
Intervention: Acanthopanax Injection (AI) 60-80 ml added to 500 ml of 0.9% normal saline, given intravenously once a day for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received 500 ml of dextra-40 given intravenously once a day for 14 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acanthopanax Injection (AI) 10 ml given intravenously once daily for 7 days in rabbit model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received 10 ml of normal saline given intravenously once daily for 7 days in rabbit model
Number of subjects: 60
Study: 8681496

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g x 3 for two weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propafenone (300 mg x 3 for two weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propafenone + L-carnitine (300 mg x 3 + 2 g x 3 at the second week)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mexiletine (200 mg x 3 for two weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mexiletine + L-carnitine (200 mg x 3 + 2 g x 3 at the second week)
Number of subjects: 50
Study: 2482304

Group type: EXPERIMENTAL
Intervention: Levorotatory disopyramide (R(‐) DP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Racemic disopyramide (equimolar mixture of R(‐) DP and S(+) DP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Racemic disopyramide (S(+) DP)
Number of subjects: 0
Study: 355647

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 17
Study: 31534062

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1578
Study: 30166422

Group type: EXPERIMENTAL
Intervention: 40 mg controlled-release oral morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28698334

Group type: EXPERIMENTAL
Intervention: Monthly text messages reminding them to test for HIV/STIs
Number of subjects: 600

Group type: COMPARATOR
Intervention: No reminders
Number of subjects: 600
Study: 26504123

Group type: EXPERIMENTAL
Intervention: Laser acupuncture combined with pharmacological therapy (morphine and phenobarbital)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (pharmacological therapy alone)
Number of subjects: 28
Study: 23361468

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (USG-TAP) block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 21885624

Group type: EXPERIMENTAL
Intervention: Incremental (INCR) cycle exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-intensity constant work-rate (CWR) cycle exercise
Number of subjects: 16
Study: 18835662

Group type: EXPERIMENTAL
Intervention: Compassion meditation (n=33)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Health discussion control group (n=28)
Number of subjects: 61
Study: 17684614

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 72

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 72
Study: 15548314

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 25 mg base/kg
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) 1.25/25 mg/kg
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Mefloquine (M) 15 mg base/kg
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MA) 15:4 mg/kg
Number of subjects: 316
Study: 11171709

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (various compositions, including high carbohydrate meals)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nutritional repletion (dietary regimen with high percentage of calories from fat)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (general)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nutritional repletion
Number of subjects: 21
Study: 9627067

Group type: EXPERIMENTAL
Intervention: CPR-plus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard method (without CPR-plus)
Number of subjects: 40
Study: 7833227

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg orally three times a day for 6 days followed by 7.5 mg zopiclone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2901220

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ranitidine 150 mg vs Ranitidine 300 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Famotidine 20 mg vs Famotidine 40 mg
Number of subjects: 8